Efforts to improve medical and endovascular treatments for intracranial stenosis depend in part on identifying risk factors associated with a high risk for recurrent stroke with each treatment. A previous article by our group studied baseline features associated with a high risk for periprocedural stroke, which constituted most of the primary end points in the stenting arm of the SAMMPRIS Trial. 12 We now report the results of an analysis to identify baseline features associated with a high risk for the primary end point in the medical group in the SAMMPRIS Trial.
Methods

Study Design and Patient Eligibility
Details of the SAMMPRIS Trial design and results have been published previously. [8] [9] [10] [11] Briefly, the SAMMPRIS Trial was a randomized, superiority, multicenter clinical trial funded by the National Institute of Neurological Disorders and Stroke (NINDS). The US Food and Drug Administration issued an Investigational Device Exemption (G050157) to perform the study with the Wingspan stent system (Stryker Neurovascular; formerly Boston Scientific Neuro-vascular), 13 which had been approved under a Humanitarian Device Exemption in 2005 for patients with 50% to 99% intracranial stenosis refractory to antithrombotic treatment. Eligible patients were 30 to 80 years old and had nondisabling stroke or transient ischemic attack (TIA) within 30 days prior to enrollment attributable to angiographically verified 70% to 99% atherosclerotic stenosis of a major intracranial artery. 14 All patients provided written informed consent to participate. Institutional review boards at all 50 participating sites in the United States approved the study protocol. Approval for the coordination of the SAMMPRIS Trial, which included this post hoc analysis (conducted from November 2014 to June 2015 , was provided by the institutional review board at the Medical University of South Carolina.
Aggressive Medical Management Treatment
The details and rationale of aggressive medical management have been published. 9 Briefly, medical treatment consisted of aspirin (325 mg daily) for the duration of follow-up and clopidogrel (75 mg daily) for 90 days after enrollment and risk-factor management, primarily targeting systolic blood pressure less than 140 mm Hg (<130 mm Hg, if diabetic) and low-density lipoprotein cholesterol level of less than 70 mg/dL (to convert to millimoles per liter, multiply by 0.0259). Additionally, diabetes mellitus and lifestyle behaviors, including smoking cessation, ideal body mass index, and exercise, were managed by the local study team working with a lifestyle modification program 15 and the primary care physician.
Duration of Follow-up and Assessment of End Points
Patients were assessed at study enrollment, 4 days, 30 days, and subsequently every 4 months until a primary end point occurred or a final closeout visit was done, which occurred during February 2013 to April 2013, 2 years after the last patient was enrolled. Patients with a suspected stroke typically underwent brain magnetic resonance imaging or computed tomography and were assessed by the primary site neurologist. A second site neurologist, blinded to treatment, assessed patients with minor events that were more difficult to classify and might have been subject to observer bias by the unblinded neurologist (ie, prolonged TIA or minor stroke associated with an increase in the National Institutes of Health Stroke Scale score of ≤3). Both neurologists' assessments were sent for central adjudication. The primary end point was any of the following: any stroke or death within 30 days after enrollment, ischemic stroke in the territory of the qualifying artery beyond 30 days of enrollment, or any stroke or death within 30 days after stenting a patient in the medical group. We defined ischemic stroke as a new focal neurological deficit of sudden onset, lasting for at least 24 hours, that was not associated with a hemorrhage on brain computed tomography or magnetic resonance imaging. Strokes were categorized as either in or out of the territory of the qualifying stenotic artery.
Statistical Methods
For the patients randomized to medical therapy only, the association between the time to the primary end point and selected baseline characteristics, including demographic features, vascular risk factors, qualifying event, brain imaging, and angiographic features, was assessed using proportional hazards regression in both bivariate and multivariable analyses.
Key Points
Question: In patients with recent transient ischemic attack or stroke attributed to 70% to 99% intracranial arterial stenosis, which patient characteristics are associated with a higher risk for recurrent stroke despite aggressive medical management?
Findings: In the medical arm of the SAMMPRIS Trial (that showed aggressive medical management alone was superior to stenting), the statistically significant baseline characteristics in multivariable analyses were old infarct in the territory of the stenotic artery on brain imaging, stroke as the qualifying event for the trial, and no statin use at enrollment.
Meaning: Although the SAMMPRIS Trial showed aggressive medical management is superior to stenting, there are subgroups at higher risk for recurrent stroke despite aggressive medical management for whom it is urgent to develop additional therapies. 9 (7.1-19.6) 14.7 (9.3-22.9) Antithrombotic at QE No 87 13 (14.9) 11.6 (6.4-20.6) 11.6 (6.4-20.6) ses, significant factors related to the primary end point were identified from among the candidate factors using backward elimination with P < .05 set for retention in the model. A Kaplan-Meier plot was constructed for each of the significant factors showing the cumulative probability of the primary end point vs time since randomization according to the levels of the factor. Patients who either withdrew from the study or were lost to follow-up before experiencing a primary end point were censored at the last study contact. Two-sided P < .05 values were considered statistically significant. All analyses were done using SAS version 9.3 (SAS Institute).
Results
There were 227 patients (mean [SD] age, 59.5 [11.8] years) randomized to aggressive medical management alone. The baseline characteristics for this treatment group as a whole have been published previously. 11 The median duration of follow-up was 32.7 months (interquartile range, 24.2-40.5; range, 0.03-52.6). There were 24 patients (11%) who either withdrew (13 patients) or were lost to follow-up (11 patients). All 11 lost patients and 7 of 13 withdrawn patients were followed up for at least 1 year. Of the 227 patients in the medical group, 34 (15%) had a primary end point during follow-up, of which 31 (91%) were ischemic strokes in the territory of the stenotic artery, 2 were ischemic strokes in another territory within 30 days of enrollment, and 1 was a nonstroke death within 30 days of enrollment.
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Bivariate Analyses
The results of the bivariate analyses are shown in Table 1 and Table 2 . These analyses identified the following factors that were associated (P < .10) with a higher risk for a primary end point: female, diabetes, no statin use at enrollment, stroke as the qualifying event, Rankin grade of 1 or greater, old infarct in the territory of the stenotic artery, and greater percentage stenosis. Only 3 of these factors were significantly associated (P < .05) with an increased risk for the primary end point: old infarct in the territory of the stenotic artery on baseline imaging (hazard ratio [HR], 2.6; 95% CI, 1.3-5.1; P = .007), absence of statin use at enrollment (HR, 2.6; 95% CI, 1.2-5.7; P = .01), and stroke rather than TIA as the qualifying event (HR, 2.5; 95% CI, 1.03-6.0; P = .04). Only 6 of 75 patients (8.0%) with TIA as the qualifying event had a primary end point, whereas 28 of 152 patients (18.4%) whose qualifying event was a stroke had a primary end point during follow-up (Table 1) .
Multivariable Analyses
The following factors with bivariate P ≤ .15 for the association with the primary end point were included as candidate by 1 and 2 years after enrollment. b Hazard ratio and P value from a Cox proportional hazard regression model relating time until a primary end point to the indicated factor with that factor as the only variable in the model. The hazard ratio is calculated for the second category relative to the first category or to the indicated reference category. c Considered diabetic at baseline if there was a history of diabetes or the baseline hemoglobin A 1c level of 6.5 mmol/mol or greater. ethnicity were also included based on outcome results from the WASID Trial, as was symptomatic artery given its clinical relevance. Because there were 7 patients missing data for 1 or more of these factors, the multivariable analysis included 220 medically treated patients. The statistically significant factors identified for the final model using backward elimination with effect size provided by HRs were: old infarct in the territory (patients with old infarct at higher risk: HR, 2.6; 95% CI, 1.3-5.3; P = .006), qualifying event (stroke patients at higher risk: HR, 3.0; 95% CI, 1.1-7.7; P = .03), and absence of statin use at enrollment (HR, 2.4; 95% CI, 1.1-5.2; P = .03) ( Table 3 ) (Figure) . Among the 48 patients with stroke as the qualifying event and an old infarct in the territory (21% of whom were not taking a statin), their 1-year and 2-year rates of a primary end point were 32.1% (95% CI, 20.7%-47.5%) and 34.3% (95% CI, 22.6%-49.8%), respectively.
For the variables not included in the final model, Table 4 shows the P values for each factor when that factor is added to a model that included old infarct in the territory, absence of statin use at enrollment, and qualifying event. Two of the factors (percentage stenosis and diabetes) had P values between .05 and ≤.10.
Discussion
Although the risk for a primary end point in the medical arm of the SAMMPRIS Trial was half of the predicted rate, [8] [9] [10] [11] this analysis shows that there are still subgroups of patients at high risk for stroke despite aggressive medical therapy. The highrisk features are the presence of an old infarct in the territory of the stenotic artery, stroke as the qualifying event, and absence of statin use at enrollment. The highest-risk patients are those who present with a new ischemic stroke and have an old infarct in the territory on brain imaging. The patients with 2 strokes in the territory before enrollment probably had unstable stenotic plaques or impaired collateral blood flow or both that put them at high risk for a third stroke in the territory. The association between the absence of statin use at enrollment and high risk for recurrent stroke is somewhat surprising given that virtually all patients in the SAMMPRIS Trial were prescribed statins at enrollment. One possible explanation for this finding is that the use of statins before enrollment may have led to earlier stabilization of the symptomatic atherosclerotic plaque in these patients, which could have lowered their early and longer-term risk for stroke.
Two other baseline features were associated with P values between .05 and ≤.10 when combined individually with old infarcts in the territory, statin use at enrollment, and stroke as the qualifying event in the multivariable analysis: percentage stenosis and diabetes. In the WASID Trial in which patients with 50% to 99% stenosis were enrolled, severe stenosis was most significantly associated with a poor outcome in medically treated patients. 7 Although the association between the severity of stenosis and outcome in the WASID Trial primarily compared patients with 70% to 99% stenosis vs less than 70% stenosis, the WASID Trial showed that the 2-year rates of stroke were 31% in patients with 80% to 89% stenosis compared with 18% in patients with 70% to 79% stenosis. 7 In the SAMMPRIS Trial, only patients with 70% to 99% stenosis were enrolled and the 2-year rates of a primary end point were 19.2% in patients with greater than 80% stenosis compared with 12.0% in patients with 70% to 79% stenosis (Table 1) . Both the bivariate and multivariable analyses showed P values for the association between diabetes and a primary end point in the range of .05 to .10. For medically managed patients, the 2-year rate of the primary end point in the SAMMPRIS Trial was 18.3% for patients with diabetes compared with 10.6% for those without diabetes (Table 1 ). In the WASID Trial, diabetes was significantly associated with an increased risk for stroke in the territory on bivariate analysis but was not significant on multivariable analysis in the WASID Trial. 7 Because both the SAMMPRIS and WASID trials had limited numbers of patients compared with most other stroke prevention trials, it is possible that there was insufficient statistical power in either the SAMMPRIS or WASID trial to establish diabetes as a statistically significant risk factor for stroke in medically treated patients. The location of stenosis that was associated with the highest primary end point rate in the medical group in the SAMMPRIS Trial was the intracranial internal carotid artery (2-year rate, 23.2%; Table 1 ). Of note, the vertebral (2-year rate, Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; QE, qualifying event.
SI conversion factors: To convert cholesterol to millimoles per liter, multiply by 0.0259; glucose to millimoles per liter, multiply by 0.0555. a Hazard ratio and P value from a Cox proportional hazard regression model relating time until a primary end point to the indicated factor with that factor as the only variable in the model. The hazard ratio is based on a 10-unit increase in the factor. In the SAMMPRIS Trial, the 2-year rate for the primary end point in the medical group was 20.1% for women and 10.7% for men (HR, 1.9; P = .06) ( Table 1 ). The association between sex and increased risk for a primary end point was weaker on the multivariable analysis, but it is of interest that female sex was associated with an increased risk for stroke in the territory on bivariate analysis (P = .047) and multivariable analysis (P = .051) in the WASID Trial. 7 The results of this study and a previous study by our group that evaluated risk factors for periprocedural stroke in the stenting arm of the SAMMPRIS Trial 12 showed that the high-risk features for recurrent ischemic stroke in both treatment arms have minimal overlap. The high risk features for periprocedural ischemic stroke in the stenting arm on multivariable analyses were older age, nonsmoking status, diabetes, and basilar artery stenosis. 12 Old infarct in the territory of the stenotic artery and nonperforator territory stroke as the qualifying event were significantly associated with periprocedural ischemic stroke in the SAMMPRIS Trial on bivariate analysis but not on multivariable analysis. 12 Despite the discordance between risk factors for recurrent stroke in both treatment groups, it is important to note that subgroup analyses in the SAMMPRIS Trial failed to show that stenting was superior to medical therapy alone in any subgroup in the SAMMPRIS Trial.
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This analysis also identified a few subgroups at particularly low risk for a primary end point while undergoing aggressive medical treatment. In particular, patients presenting with TIA alone had 1-and 2-year rates of a primary end point of only 5.6% and 7.0%, respectively (Table 1) . Patients who were already in target for exercise at study entry also had low rates of the primary end point at 1 and 2 years (7.8% at both points; Table 1 ). These results supplement the risk factor analyses from the SAMMPRIS Trial showing that exercise during follow-up was the most important determinant of a good outcome in the medical arm.
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This study had some limitations, including the post hoc nature, multiple comparisons, and the limited sample size, which was a result of enrollment being stopped early because 
